Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about trying PTD-DBM for hair loss treatment. Users are curious about its effectiveness and results.

The user has been using minoxidil for hair loss and is considering trying a compounded topical treatment with 0.1% dutasteride, minoxidil, tretinoin, collagen, and silicon, as recommended by a trichologist. They learned that dutasteride might be more effective than finasteride and are seeking opinions on the use of topical dutasteride.

Dutasteride Mesotherapy shows promising hair growth results without affecting serum DHT levels, but the study's small sample size of six patients limits its reliability. The treatment is expensive and not widely available, with concerns about the lack of standardized procedures and long-term research.

Reducing sebum can indirectly lower DHT levels, with treatments like accutane, tretinoin, and green tea extract acting as DHT blockers. Accutane can lower DHT levels by reducing 5α-reductase activity, but its impact on hair varies.

PP405 is being discussed as a potential hair loss treatment, possibly more effective than minoxidil. There are concerns about its effectiveness and product contamination, but some users report early signs of hair regrowth.

The conversation questions the lack of feedback on the effectiveness of PGE2 and setipiprant for hair loss, despite their availability. The user is puzzled by the absence of reviews or results, whether positive or negative.

The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.

A user experienced worsened hair condition after a PRP session and is considering stopping further sessions. They are using a Dermapen, electric massage, iron, saw palmetto, and plan to start minoxidil, but have had side effects with finasteride and are advised to consider dutasteride under medical supervision.

Topical finasteride reduces scalp DHT, with some going systemic. Using 0.025% at 1ml per day can stabilize hair loss without side effects.

A user experienced increased hair density loss after 4 months on dutasteride combined with finasteride. They are also using topical dutasteride with azelaic acid and alfatradiol but cannot tolerate antiandrogens like RU58841 due to headaches.

The conversation discusses the use of pyrrolidinyl diaminopyrmidine oxide (triaminodil) compared to minoxidil for hair loss treatment. The user is considering switching from 5% minoxidil to a product containing 5% triaminodil.

PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.

Adding RU58841 to Dutasteride treatment helped reduce hair shedding significantly for several users. Some reported no change with RU58841, while others experienced a dramatic decrease in shedding and increased hair density.

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.

User experienced hair loss since 16, used Fin, Minox, and Nizoral with success but stopped due to side effects. Now using Pur D'or shampoo, Rogaine foam, scalp massages, volumizing spray, and dermarolling for hair maintenance.

The user is concerned about low DHT levels due to using saw palmetto in Foligain supplements and is considering trying finasteride. They seek advice on whether finasteride will also lower DHT and how to manage DHT levels.

Low-dose dutasteride (0.1 mg) is effective for hair growth, potentially more so than finasteride, with fewer side effects. East Asians may respond well to these treatments due to hair characteristics.

The conversation discusses using RU58841 mixed with topical minoxidil for hair loss, noting its chemical instability and storage challenges. A user shares their experience using RU58841 with ethanol and propylene glycol, mentioning no significant results yet.

The conversation is about finding the best method to lower scalp prolactine, with suggestions like P5P and Melatonin. The user also mentions HMI115 as a potential treatment and seeks feedback from those who have tried these methods.

The conversation is about exploring alternatives for hair loss treatment, specifically ds laboratory revita shampoo and nanoxidil, with the user currently using microneedling. The user is considering these options due to fewer side effects compared to other treatments.

The conversation discusses skepticism about group buys for hair loss treatments, highlighting issues with unverified chemicals and the risks involved. It suggests stabilizing with dutasteride and minoxidil, and considering a hair transplant instead of experimenting with untested products.

The conversation discusses using very low dose topical finasteride to achieve specific serum DHT reduction percentages. It concludes that finasteride dosage increases linearly between 5-30% DHT reduction but requires exponential increases for reductions up to 70%.

Higher doses of dutasteride, such as 2.5mg, are more effective at reducing scalp DHT than 0.5mg, but are costly and inconvenient. A 1mg dose is considered a more affordable and practical option, though its efficacy is uncertain.

Clascoterone 5% shows potential for hair thickening and darkening, especially when combined with treatments like finasteride. It may be a good alternative for those who experience side effects from other treatments.

The conversation discusses the safety and cost of 2.5mg Dutasteride, and the potential for increased DHT reduction by combining Dutasteride with topical Finasteride. The original poster is currently using 0.5mg Dutasteride, 1.25mg oral Minoxidil, and a topical treatment, and is considering increasing the dosage to maximize results while avoiding less known treatments like RU58841.

The efficacy of low doses of finasteride to reduce scalp DHT, and whether studies showing a 61% reduction are reflected in actual results. Replies discussed hair growth as an unintended consequence of minoxidil and finasteride use, as well as self-selective bias, potential side effects, and that studies measure effectiveness by hair count changes rather than DHT inhibition.

Koshine KX-826 has different versions, and the green version uses a plant-based carrier that may be less irritating for those sensitive to propylene glycol. Users report irritation with some versions of KX-826.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

The conversation is about a user trying to fund lab testing for RU58841 to verify its legitimacy, as there are doubts about its effectiveness. Some users express skepticism about RU58841, suggesting alternatives like KX-826.

The conversation discusses severe hair shedding and thinning, with the original poster using finasteride, oral minoxidil, and other supplements without improvement. The discussion highlights the possibility of telogen effluvium and the importance of addressing potential underlying health issues, such as stress and gut health, rather than assuming diffuse unpatterned alopecia (DUPA).